12/4/2024

Janusmed amning

Janusmed amning – WEZENLA

Janusmed amning tillhandahåller generella rekommendationer om huruvida ett friskt fullgånget spädbarn kan ammas när modern använder olika läkemedel. Observera att prematura och/eller sjuka spädbarn alltid kräver särskilda överväganden. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed amning och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Ustekinumab

Ustekinumab

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology. 2018;155(3):696-704.

  2. Klenske E, Osaba L, Nagore D, Rath T, Neurath MF, Atreya R. Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease. J Crohns Colitis. 2019;13(2):267-269.

  3. Bar-Gil Shitrit A, Ben-Horin S, Mishael T, Hoyda A, Yavzori M, Picard O et al. Detection of Ustekinumab in Breast Milk of Nursing Mothers With Crohn Disease. Inflamm Bowel Dis. 2021;27(5):742-745.

  4. Saito J, Kaneko K, Kawasaki H, Hayakawa T, Yakuwa N, Suzuki T et al. Ustekinumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum. J Pharm Health Care Sci. 2022;8(1):18.

  5. Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. Dermatol Ther. 2017;30(3).

  6. Mugheddu C, Atzori L, Lappi A, Murgia S, Rongioletti F. Biologics exposure during pregnancy and breastfeeding in a psoriasis patient. Dermatol Ther. 2019;32(3):e12895.

  7. Mitrova K, Pipek B, Bortlik M, Bouchner L, Brezina J, Douda T et al. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study. J Crohns Colitis. 2022;16(12):1808-1815.

  1. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology. 2018;155(3):696-704.
  2. Klenske E, Osaba L, Nagore D, Rath T, Neurath MF, Atreya R. Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease. J Crohns Colitis. 2019;13(2):267-269.
  3. Bar-Gil Shitrit A, Ben-Horin S, Mishael T, Hoyda A, Yavzori M, Picard O et al. Detection of Ustekinumab in Breast Milk of Nursing Mothers With Crohn Disease. Inflamm Bowel Dis. 2021;27(5):742-745.
  4. Saito J, Kaneko K, Kawasaki H, Hayakawa T, Yakuwa N, Suzuki T et al. Ustekinumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum. J Pharm Health Care Sci. 2022;8(1):18.
  5. Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. Dermatol Ther. 2017;30(3).
  6. Mugheddu C, Atzori L, Lappi A, Murgia S, Rongioletti F. Biologics exposure during pregnancy and breastfeeding in a psoriasis patient. Dermatol Ther. 2019;32(3):e12895.
  7. Mitrova K, Pipek B, Bortlik M, Bouchner L, Brezina J, Douda T et al. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study. J Crohns Colitis. 2022;16(12):1808-1815.

Innehållet senast uppdaterat 11/7/2024